Qiagen (NYSE:QGEN) Stock Rating Cut to “Equal Weight” at Barclays

Qiagen (NYSE:QGEN) was downgraded by analysts at Barclays from an “overweight” rating to an “equal weight” rating in a note issued to investors on Wednesday, Benzinga reports. They presently have a $53.00 target price on the stock, down from their prior target price of $55.00. Barclays‘s price target would suggest a potential upside of 5.57% from the company’s current price.

A number of other equities analysts also recently commented on QGEN. Jefferies Financial Group restated a “buy” rating and set a $48.00 target price on shares of Qiagen in a report on Thursday, August 6th. Citigroup reaffirmed a “neutral” rating and issued a $52.00 price target (up from $45.00) on shares of Qiagen in a research note on Monday. UBS Group began coverage on shares of Qiagen in a report on Wednesday, September 9th. They issued a “neutral” rating and a $47.00 price target on the stock. JPMorgan Chase & Co. reissued a “neutral” rating and set a $52.00 price objective (down from $55.00) on shares of Qiagen in a research report on Thursday, October 22nd. Finally, Morgan Stanley restated an “overweight” rating on shares of Qiagen in a report on Friday, September 11th. Four analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $46.09.

Qiagen Trading Down 0.3%

Qiagen stock opened at $50.20 on Wednesday. The firm has a 50-day moving average of $44.73 and a 200-day moving average of $42.70. Qiagen has a 1-year low of $32.53 and a 1-year high of $57.81.

Qiagen (NYSE:QGEN) last posted its earnings results on Wednesday, August 5th. The company reported $0.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.60 by $0.02. The business had revenue of $535.04 million during the quarter, compared to the consensus estimate of $527.50 million. During the same period in the previous year, the business earned $0.60 earnings per share. The firm’s revenue for the quarter was up .2% compared to the same quarter last year. Qiagen has set its FY 2026 guidance at 2.430- EPS. On average, analysts expect that Qiagen will post 2.44 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Childress Capital Advisors LLC raised its position in shares of Qiagen by 23.8% in the 3rd quarter. Childress Capital Advisors LLC now owns 9,091 shares of the company’s stock worth $398,000 after acquiring an additional 1,745 shares in the last quarter. North Dakota State Investment Board bought a new stake in shares of Qiagen during the third quarter valued at approximately $276,000. Generali Asset Management SPA SGR bought a new stake in shares of Qiagen during the third quarter valued at approximately $2,335,000. Signaturefd LLC purchased a new stake in Qiagen in the third quarter worth $367,000. Finally, Evergreen Capital Management LLC purchased a new stake in Qiagen in the third quarter worth $587,000. Hedge funds and other institutional investors own 70.00% of the company’s stock.

About Qiagen

QIAGEN N.V. (NYSE:QGEN) is a global provider of sample preparation technologies, molecular testing solutions and bioinformatics for the life sciences and molecular diagnostics markets. The company develops products that help researchers and clinical laboratories isolate, analyze and interpret DNA, RNA and other biological materials.

Its portfolio includes sample collection and purification kits, automated laboratory instruments, PCR and next-generation sequencing assays, digital PCR solutions, bioinformatics software and related consumables.